Showing 339 news articles about PrEP policies & guidelines

Filters Content type: Editors' picks Topic: PrEP policies & guidelines

Health service and government policies on the licensing, provision and reimbursement of oral pre-exposure prophylaxis (PrEP). Expert guidelines, based on research evidence, to help clinicians provide care to PrEP users.

PrEP policies & guidelines

MHRA approves lenacapavir for the prevention of sexually transmitted HIV-1 infection

Editor's pick
Medicines and Healthcare products Regulatory Agency (MHRA)
22 December 2025
Government, leadership & policy

Top 10 HIV Clinical Developments of 2025

Editor's pick
TheBodyPro
15 December 2025
PrEP policies & guidelines

South Africa wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch

Editor's pick
Bhekisisa
8 December 2025
PrEP policies & guidelines

New Canadian HIV Guideline Emphasizes Patient Role in PrEP Decisions

Editor's pick
Medscape (requires free registration)
8 December 2025
PrEP science

Oral PrEP for HIV Starts Working Faster Than You Might Think

Editor's pick
TheBody
1 December 2025
PrEP policies & guidelines

Canada: New guideline on pre-exposure and postexposure HIV prevention

Editor's pick
EurekAlert!
1 December 2025
PrEP policies & guidelines

Breakthrough HIV prevention jab given green light in South Africa

Editor's pick
Spotlight
27 October 2025
PrEP policies & guidelines

NICE approves annual access to injectable cabotegravir PrEP in England for 1000 people

Editor's pick
i-Base
17 October 2025
PrEP policies & guidelines

NHS to roll out first long-acting injection to prevent HIV

Editor's pick
NHS England
17 October 2025
PrEP policies & guidelines

Joint Statement: Activists Demand $40-a-Year Generic Price for Breakthrough HIV Prevention Drug Be Made Available to All Low- and Middle Income Countries

Editor's pick
Treatment Action Group
25 September 2025
PrEP policies & guidelines

Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily HIV prevention pill

Editor's pick
Bhekisisa
24 September 2025
Injectable & long-acting PrEP

Support for Indian Manufacturers to Produce Cheap Generics of HIV ‘Miracle’ Drug, Lenacapavir

Editor's pick
Health Policy Watch
24 September 2025
Injectable & long-acting PrEP

CDC 'strongly' backs Gilead's HIV PrEP Yeztugo, but advocacy groups say access barriers remain

Editor's pick
FiercePharma
23 September 2025
PrEP policies & guidelines

UK: Pharmacies must be part of national HIV prevention strategies, researchers urge

Editor's pick
The Pharmaceutical Journal
19 September 2025
Pharmaceutical industry

Lenacapavir in South Africa: There are mounting concerns over transparency in cost

Editor's pick
Health-E News
15 September 2025
PrEP policies & guidelines

U.S. will fulfill Biden-era pledge to provide lenacapavir PrEP to millions

Editor's pick
Science
8 September 2025
Injectable & long-acting PrEP

Why the medical community is thrilled by U.S. support for a 'breakthrough' HIV drug

Editor's pick
NPR
5 September 2025
Injectable & long-acting PrEP

US: CVS Will Not Cover Long-Acting HIV PrEP Lenacapavir For Now

Editor's pick
POZ
5 September 2025
Access to healthcare

PrEP Insurance Denials Occur Frequently in U.S., Nationwide Survey Reveals

Editor's pick
TheBodyPro
4 September 2025
Injectable & long-acting PrEP

South Africa plans anti-HIV jab roll-out at 300+ clinics by April

Editor's pick
Bhekisisa
28 August 2025
Injectable & long-acting PrEP

EU approves Gilead's new injection for preventing HIV

Editor's pick
Reuters
28 August 2025
PrEP policies & guidelines

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

Editor's pick
FiercePharma
25 August 2025
Injectable & long-acting PrEP

We Have More PrEP Options Than Ever In The U.S.—But Who Will Be Able To Afford Them?

Editor's pick
TheBody
25 August 2025
Finance & funding

NIH ponders overhauling HIV budget to capitalize on prevention breakthrough

Editor's pick
Science Magazine
12 August 2025